Aspirin and non-aspirin non-steroidal anti-inflammatory drug use and risk of lung cancer

Saw Swee Hock School of Public Health, National University of Singapore, MD3, 16 Medical Drive, Singapore 117597, Singapore. wei-yen
Lung cancer (Amsterdam, Netherlands) (Impact Factor: 3.74). 04/2012; 77(2):246-51. DOI: 10.1016/j.lungcan.2012.03.005
Source: PubMed

ABSTRACT There is evidence that aspirin and non-aspirin non-steroidal anti-inflammatory drug (NSAID) have anti-carcinogenic properties, but their effect on lung cancer, in particular in never-smokers, is unclear. Information on past or current use of anti-inflammatory medication was obtained in 398 Chinese female primary lung cancer cases and 814 controls in a hospital-based study in Singapore. 65% of cases and 88% of controls were never-smokers. Controls were excluded if they had been admitted for conditions associated with aspirin or NSAID use (n=174). Regular aspirin use (twice a week or more, for a month or more) was associated with a reduced risk of lung cancer (adjusted odds ratio [OR] 0.50, 95% confidence intervals [95%CI] 0.31-0.81 in non-smokers; OR 0.38, 95%CI 0.16-0.93 in smokers). Regular use of non-aspirin NSAID, paracetamol, steroid creams and steroid pills was uncommon and no association with lung cancer was detected. Our results suggest that aspirin consumption may reduce lung cancer risk in Asian women and are consistent with current understanding of the role of cyclooxygenase in lung carcinogenesis.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives Aspirin (ASA) has been frequently used for thrombo-prophylaxis in patients with multiple myeloma (MM) when treated with thalidomide or lenalidomide. Despite the well-recognized chemo-preventive role of ASA in some solid tumors particularly for colon cancer, whether ASA displays the anti-myeloma activity remains unclear.MethodsMM1.S and RPMI-8226 cell lines harboring K-Ras and N-Ras mutation respectively were treated with various concentrations of ASA for different hours. The cell proliferation and apoptosis were performed to explore the effects of ASA on myeloma. Then the exact mechanisms governing ASA's antimyleoma were explored by qRT-PCR and Western blot. Also, the effect of ASA on tumor growth was observed in NOD/SCID mice bearing myeloma xenografts.ResultsASA of 0~10mM concentration inhibits proliferation MM1.S and RPMI-8226 cells in time- and dose-dependent manner. The myeloma cells exposed to ASA treatment displayed concentration-dependent apoptosis, which was closely associated with activation of caspases, upregulation of Bax, and downregulation of Bcl-2 and VEGF. Study in vivo revealed that ASA administration retarded the tumor growth accompanying the survival time of mice bearing myeloma xenografts.ConclusionsASA exerted anti-proliferative and pro-apoptotic action in myeloma cells in vitro and delayed the growth of human myeloma cells in vivo. The underlying mechanisms were ascribed to regulation of Bcl-2 and Bax and suppression of VEGF.This article is protected by copyright. All rights reserved.
    European Journal Of Haematology 04/2014; DOI:10.1111/ejh.12352 · 2.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with rheumatoid arthritis (RA) appear to be at a higher risk of lung cancer (LC). Although the connection between RA and LC has been an active area of research for many years, the molecular pathogenesis of the disease process remains unclear. The cyclooxygenase (COX)-2/thromboxane A2 (TxA2) pathway has been shown to play a potential role in LC development through an auto-regulatory feedback loop. An increased level of TxA2 has been found in RA patients, and intriguingly, the positive feedback loop for the COX-2/TxA2 pathway was shown to have a potential function in RA fibroblast-like synoviocytes (RA-FLS). Thus, the molecular basis of LC development in patients with RA has been at least in partly described. It is possible that COX-2-derived TxA2 could be monitored for the early detection of LC in RA patients, and targeting this molecular may decrease the risk of LC in patients with RA.
    Cancer Letters 08/2014; 354(1). DOI:10.1016/j.canlet.2014.08.024 · 5.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Inflammatory stimuli clearly contribute to lung cancer development and progression, but the underlying pathogenic mechanisms are not fully understood. We found that the pro-inflammatory cytokine IL-1β is dramatically elevated in the serum of patients with non-small cell lung cancer (NSCLC). In vitro studies showed that IL-1β promoted the proliferation and migration of NSCLC cells. Mechanistically, IL-1β acted through the COX-2/HIF-1α pathway to repress expression of miR-101, a microRNA with an established role in tumor suppression. Lin28B was identified as critical effector target of miR-101 with its repression of Lin28B a critical aspect of tumor suppression. Overall, IL-1β upregulated Lin28B by downregulating miR-101. Interestingly, COX-2 inhibition by aspirin or celecoxib abrogated IL-1β-mediated repression of miR-101 and IL-1β-mediated activation of Lin28B, along with their stimulatory effects on NSCLC cell proliferation and migration. Together, our findings defined a IL-1β/miR-101/Lin28B pathway as a novel regulatory axis of pathogenic inflammatory signaling in NSCLC.
    Cancer Research 06/2014; 74(17). DOI:10.1158/0008-5472.CAN-14-0960 · 9.28 Impact Factor